Portfolio Management Healthcare

  • Since 2004 with Bellevue Asset Management as head biotech, portfolio manager of the BB Biotech (Lux) Fund and head of the investment company BB Biotech Ltd
  • 2001 - 2004 equity4life Asset Management Ltd, investment manager
  • 2000 - 2001 UBS Warburg, equity analyst
  • Master's degree in Biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich
  • PhD in Biotechnology of the Swiss Federal Institute of Technology (ETH) Zurich and Cytos Biotechnology Ltd, Zurich
 
  • Since 2004 with Bellevue Asset Management as senior biotech analyst and Head Bellevue Research Inc
  • 1999 - 2004 Adams, Harkness & Hill, biotech equity analyst
  • 1991 - 1999 SG Cowen, biotech equity analyst
  • MBA, Suffolk University, Boston
  • BA in Communications, Boston College
     
 
  • Since October 2013 with BB Biotech as Portfolio Manager specializing in neurologic and psychiatric diseases
  • 2009-2013 Iguana Healthcare Partners, Senior Analyst and Founding Partner
  • 2008-2009 Merlin BioMed Group, Consultant
  • 2004-2008 Mount Sinai Hospital, New York, National Institutes of Health M.D./Ph.D. Fellow in Neuroscience
  • M.D. and Ph.D. in Neuroscience, Brown University School of Medicine


 

 
  • Since 2006 with Bellevue Asset Management as analyst/portfolio manager biotech
  • 2004-2006 Standford Group Company, senior vice president, equity analyst
  • 2003-2004 Sterling Financial Investment Group, equity analyst
  • 2002-2003 Adams, Harkness & Hil, vice president, associate analyst
  • MBA, Texas Christian University
  • BA in Microbiology and Zoology, Louisiana State University

 

 
  • Analyst and Portfolio Manager at BB Biotech since September 1, 2014
  • 2013-2014 Sell-side Pharma & Biotech Equity Analyst at Bank am Bellevue in Küsnacht
  • 2010-2013 Research Associate at the Institute of Pharmaceutical Sciences, ETH Zurich
  • Doctorate in Chemoinformatics & Computational Drug Design, ETH Zurich
  • Degree in Bioinformatics, Goethe University Frankfurt
 
  • Since 2011 Research Analyst at Bellevue Asset Management for the investment company BB Biotech
  • 2011 Master of Science at ETH Zürich in Systems Biology, with distinction
 
  • Since 2008 with Bellevue Asset Management as lead portfolio manager of the BB Medtech (Lux) Fund
  • 2004 - 2008 Sonova, head investor relations
  • 2000 - 2004 Obtree Technologies Inc., finance and investor relations
  • 1996 - 2000 Bank Sarasin, medtech analyst
  • Master’s degree in Business Economics, University of St. Gallen (HSG), CEFA charterholder
 
  • Since 2008 with Bellevue Asset Management as portfolio manager of the BB Medtech (Lux) Fund
  • 2004 - 2008 Deloitte & Touche LLP, business consultant with focus on the medtech and pharmaceutical sectors
  • Master’s degree in Business Economics, University of St. Gallen (HSG)

 

 

 
  • Since 2004 with Bellevue Asset Management as Head and senior investment advisor Venture Capital
  • 2002 - 2004 Global Life Science Ventures, investment manager venture capital
  • 1994 - 2002 McKinsey & Co. Zurich and New York, associate partner, consulting for international pharmaceutical companies
  • 1992 - 1994 University Hospital of Basel, resident physician
  • various board assignments with medtech and biotech companies
  • MD from the University of Basel
  • MBA, INSEAD Fontainebleau, France
     
 
  • Since 2004 with Bellevue Asset Management as a senior investment advisor biotech ventures
  • Various board assignments with biotech companies in Switzerland and the US
  • 1999 - 2004 NMT and HBM BioVentures/BioMedinvest, investment manager venture capital
  • 1998 - 1999 Sanofi-Synthélabo, strategic marketing
  • PhD in Protein Chemistry, Swiss Federal Institute of Technology (ETH) Zurich
  • MSc in Biochemistry and a Master's degree in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH) Zurich
  • Studies at the Eberhard Karls Universitity of Tubingen, Germany

 

 

 

  • Since 2004 with Bellevue Asset Management as senior investment advisor venture capital
  • 2001 - 2004 Global Life Science Ventures, investment manager venture capital
  • 2000 - 2001 Booz Allen & Hamilton, management consultant
  • 1995 - 2000 Scientific research at the Swiss Federal Institute of Technology (ETH) Zurich and at the Center of Molecular Biology of University of Heidelberg / ZMBH, Germany
  • PhD degree in Molecular Biology, University of Heidelberg
  • Master's degree in Chemistry, University of North Carolina, USA

 

 
 
  • 1995 - present Asset Management BAB N.V., Curaçao, Managing Director / Portfolio Management
  • 1990 - 1995 CITCO Account Manager Securities Administration
  • 1985 - 1989 Multilift, Head Administration
  • 1984 - 1985 Higher Economic Education (HEAO)

 

 
 

  • 2001 - present BB Biotech subsidiary, Curaçao, Chairman
  • 2000 - 2001 CITCO, Managing Director
  • 1992 - 2000 Ernst & Young, Netherlands and the Netherlands Antilles
  • 1984 - 1992 Tax law, University of Leiden, the Netherlands

 

 
  • 2007 - present Asset Management BAB N.V., Curaçao, Portfolio Management
  • 2006 - 2007 NMT Services N.V., Account Manager / Securities Administrator
  • 1997 - 2006 Decro Trust N.V., Securities Administration for large Dutch investment compan
  • 1992 - 1996 CITCO, Securities Administration
  • 2004 - 2005 Modern business administration
     

 

 
  • Board member and managing director of the BB Biotech branch office in Curaçao since 2013
  • Various executive positions with the National Laboratory of Curaçao
  • Operational director and still partner at a local Curaçao private medical laboratory
  • Degree in medical science from the Emory University in Atlanta, USA